Cognition Therapeutics Inc at JMP Securities Life Sciences Conference Transcript
Welcome back to the next session here. It is my pleasure to introduce Lisa Ricciardi, President & CEO of Cognition Therapeutics. Thank you so much for joining us.
Pleasure. Thanks for having me. Thank you all for coming, making it in on such a miserable day. We are public company, so please look at our forward-looking statement. If you are not familiar with Cognition, in brief, a couple of things to tell you -- age-related neurodegenerative disorders. This has been the company's focus and history.
That specifically means Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, and dry age-related macular degeneration. Our scientific founder had an interest in synaptic biology -- learning and memory. That's the history of the company, and that is why we have ended up with the expertise and depths we have.
Now since today was the morning we all read about Roche, let me just say this once and I will say it later, our drug does not target A-beta
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |